Sari Reisner on the benefits of gender-affirming hormone therapy on HIV clinical outcomes episode artwork

EPISODE · Mar 27, 2025 · 21 MIN

Sari Reisner on the benefits of gender-affirming hormone therapy on HIV clinical outcomes

from The Lancet HIV in conversation with · host The Lancet Group

Sari Reisner (University of Michigan School of Public Health, Boston, USA) on gender-affirming hormone therapy for transgender, non-binary, and gender-diverse people in the US and its effects on HIV acquisition risk and viral suppression. Read the article: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00004-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhiv And the personal view: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(24)00299-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhiv Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Mar 27, 2025

Embed this episode

Ready to play

Sari Reisner on the benefits of gender-affirming hormone therapy on HIV clinical outcomes

0:00 21:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet HIV in conversation with?

This episode is 21 minutes long.

When was this The Lancet HIV in conversation with episode published?

This episode was published on March 27, 2025.

Can I download this The Lancet HIV in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!